Reuters logo
BRIEF-Sorrento therapeutics anti-CEA car-T demonstrates promising clinical activity and safety in phase IB clinical trial
April 3, 2017 / 6:14 PM / 8 months ago

BRIEF-Sorrento therapeutics anti-CEA car-T demonstrates promising clinical activity and safety in phase IB clinical trial

April 3 (Reuters) - Sorrento Therapeutics Inc

* Sorrento therapeutics anti-cea car-t demonstrates promising clinical activity and safety in phase IB clinical trial

* In addition, from a safety standpoint, HITM-SIR protocol was well tolerated

* There were no grade 4 or grade 5 events related to anti-cea car-t, sirt, or combination

* All colitis episodes resolved with il-2 dose reductions

* Sorrento - “anti-cea car-t hai may represent a safe & well tolerated component of novel multi-modality regimens capable of meaningful disease control.” Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below